Clinical Trial Update: Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab with the CXCR4 antagonist BL-8040 in metastatic pancreatic cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• BL-8040
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-02-19